Qyuns Therapeutics Forms Strategy and Development Committee to Sharpen Long-Term Planning

Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) just unveiled an update.

Qyuns Therapeutics has created a Strategy and Development Committee under its board to better manage the company’s long-term strategic development and major investment decisions. The move is intended to enhance core competitiveness, improve the scientific rigor of decision-making, and standardize procedures in line with PRC company law and Hong Kong listing requirements.

The committee will consist of at least three directors, including a chairperson appointed by the board, and members will be nominated by the board chair, a majority of independent non-executive directors, or one-third of all directors. Members serve terms concurrent with the board, with automatic lapse of committee membership if they cease to be directors, and any resulting vacancies filled by new board appointees under the same terms.

The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.

More about Qyuns Therapeutics Co., Ltd. Class H

Qyuns Therapeutics Co., Ltd. operates in the biopharmaceutical sector and focuses on therapeutic products, with its shares listed in Hong Kong. The company is working to strengthen its strategic planning and investment decision-making framework to support long-term development in a competitive healthcare market.

Average Trading Volume: 241,118

Technical Sentiment Signal: Sell

Current Market Cap: HK$4.29B

For a thorough assessment of 2509 stock, go to TipRanks’ Stock Analysis page.